We are stronger together. We aspire to perform more powerfully by collaborating more confidently and building intimate relationships based on trust, respect, and integrity for a better tomorrow.
Inspirevax (formerly Biodextris)
In March 2021, Oragenics entered into a material transfer agreement with Inspirevax for the use of three intranasal immune response adjuvants. Our collaboration with Inspirevax allows for the evaluation of specific intranasal adjuvants to be studied in preclinical hamster and mouse immunogenicity testing.
Adjuvance strives to improve human health by preventing diseases and infections through effective adjuvants and licensing partnerships. Oragenics’ collaboration with Adjuvance allows us to explore the use of their synthetic vaccine adjuvant for intramuscular administration.
National Research Council of Canada
The NRC is Canada’s largest federal research and development organization, partnering with Canadian industries to take research from the lab to the marketplace.
In July 2021, Oragenics’ collaboration with the NRC provided us with antigen expression cell line technology capable of producing spike proteins within six to eight weeks.
National Institutes of Health
In March 2020, Oragenics obtained a nonexclusive license from the NIH for its DNA sequence to create our spike protein. Our collaboration with the NIH allows for the utilization of technology licensed from NIH that stabilizes the Terra CoV-2 spike antigen in the pre-fusion state.
Learn more here: www.nih.gov/about-nih/who-we-are
Florida International University
Since 2017, Oragenics has been collaborating with Florida International University (FIU) to develop molecular modeling methods to study lantibiotics further. We are hopeful that this collaboration will help us discover additional compounds for fighting infectious diseases.